Is there a need for rescreening of patients treated for genital chlamydial infections?
The present communication reviews reasons to perform rescreening of chlamydia-infected persons. It brings up difficulties to differentiate between relapse and reinfection. Studies on follow-up of chlamydia-positive cases after therapy are reviewed. It also highlights reasons for therapeutic failure, like compliance, pharmacological factors, including poor bioavailability, wrong dose regimens, lack of adherence to drug intake, neglect of partner notification and concomitant therapy in consorts, possible development of resistance to drugs generally prescribed, false negative or false positive diagnostic tests and reinfection from extra-genital not 'cured' sites. The review points to the need to establish programmes for routine rescreening of chlamydia-infected persons.
Mårdh
Per-Anders
PA
Persson
Kenneth
K
D000935:Antifungal Agents / Q000008:administration & dosage / Q000627:therapeutic use; D002690:Chlamydia Infections / Q000175:diagnosis* / Q000188:drug therapy* / Q000382:microbiology; D002692:Chlamydia trachomatis / Q000187:drug effects / Q000302:isolation & purification; D016358:Contact Tracing; D005260:Female; D005831:Genital Diseases, Female / Q000175:diagnosis* / Q000188:drug therapy / Q000382:microbiology; D005832:Genital Diseases, Male / Q000175:diagnosis* / Q000188:drug therapy / Q000382:microbiology; D006801:Humans; D008297:Male; D008403:Mass Screening; D012008:Recurrence
D000935:Antifungal Agents